Physician

Marcus Elijah Babaoff, M.D.

According to 2025 Medicare claims, Marcus Babaoff, M.D. (NPI: 1861650590) practices family practice in the Burlington, NC market, with the plurality of this provider's patient population coming from Alamance, NC. This provider's primary affiliated billing organization is DUKE HEALTH INTEGRATED PRACTICE, INC. (NPI: 1205553369; TIN: 862109896) and primary practice location at 27244-9280. Babaoff is affiliated with the Duke Connected Care, LLC (ACO ID: A2419) and Triad HealthCare Network, LLC. (ACO ID: D0209), participating under both the MSSP and REACH models.

Babaoff's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 227 traditional Medicare patients, billed 3,417 HCPCS/CPT codes, and received $91,163 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 10,584 prescription claims across 703 beneficiaries totaling $610,244 in drug costs, led by Eliquis (Apixaban). DME data shows 205 claims. Open Payments data shows 1 records totaling $27. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Similarly, Part D prescription costs have changed little. In contrast, DME billing represents a smaller volume and moved from a lower plateau to a higher plateau, from $3,565 to $9,222.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	372	3,231	$97,210
2016	357	3,130	$81,034
2017	318	3,093	$83,423
2018	321	3,112	$84,433
2019	319	3,135	$89,466
2020	298	3,242	$85,729
2021	292	3,937	$103,010
2022	281	4,027	$101,436
2023	253	3,864	$94,223
2024	227	3,417	$91,163

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	752	11,420	$548,968
2016	727	12,466	$583,430
2017	716	11,952	$497,184
2018	674	11,177	$438,806
2019	703	10,322	$470,616
2020	680	9,909	$528,997
2021	675	9,638	$550,415
2022	714	9,692	$604,024
2023	709	10,098	$618,035
2024	703	10,584	$610,244

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	33	101	$2,699
2016	16	103	$1,885
2017	15	58	$710
2018	N/R	51	$796
2019	12	113	$2,753
2020	13	116	$3,037
2021	48	219	$7,529
2022	11	170	$5,875
2023	N/R	172	$6,927
2024	39	205	$7,340

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	213	437	$74
80061	Blood test, lipids (cholesterol and triglycerides)	185	304	$13
80053	Blood test, comprehensive group of blood chemicals	198	335	$10
36415	Insertion of needle into vein for collection of blood sample	197	344	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	198	329	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	107	5,234	$100,474
Ozempic	Semaglutide	68	2,520	$79,293
Jardiance	Empagliflozin	48	2,835	$54,618
Mounjaro	Tirzepatide	24	840	$30,822
Tradjenta	Linagliptin	17	810	$13,982

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A7030	Full face mask used with positive airway pressure device, each	N	N/R	19	$1,703
E0601	Continuous positive airway pressure (cpap) device	Y	N/R	43	$1,499
A7031	Face mask interface, replacement for full face mask, each	N	N/R	14	$1,422
A4604	Tubing with integrated heating element for use with positive airway pressure device	N	12	27	$1,035
A7034	Nasal interface (mask or cannula type) used with positive airway pressure device, with or without head strap	N	N/R	15	$717

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$27	Astellas Pharma US Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Marcus Elijah Babaoff, M.D.?

Tedicare shows public-source Medicare data for Marcus Elijah Babaoff, M.D. (NPI 1861650590), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Marcus Elijah Babaoff, M.D. have ACO affiliation data?

Marcus Elijah Babaoff, M.D. is shown with ACO affiliation data for Duke Connected Care, LLC (MSSP, ACO ID A2419) and Triad HealthCare Network, LLC. (REACH, ACO ID D0209).

What billing organization is linked to Marcus Elijah Babaoff, M.D.?

Marcus Elijah Babaoff, M.D. is linked to DUKE HEALTH INTEGRATED PRACTICE, INC. (billing NPI 1205553369) in the available physician profile data.

Does Marcus Elijah Babaoff, M.D. have Open Payments data?

Marcus Elijah Babaoff, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.